Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease

Behavioural Pharmacology

Volumn 22, Issue 7, 2011, Pages 681-692

  McFarland, Krista ^a   Price, Diana L ^a   Bonhaus, Douglas W ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

6 hydroxydopamine lesion; animal model; dopamine depletion; Parkinson's disease psychosis; rat; serotonin; substantia nigra

Indexed keywords

AMPHETAMINE; OXIDOPAMINE; PIMAVANSERIN; VOLINANSERIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; DRUG DERIVATIVE; FENFLURAMINE; FLUOROBENZENE; N (4 FLUOROPHENYLMETHYL) N (1 METHYLPIPERIDIN 4 YL) N' (4 (2 METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE; N-(4-FLUOROPHENYLMETHYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR AFFECTING AGENT; TYROSINE 3 MONOOXYGENASE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN DAMAGE; CLINICAL EXAMINATION; CONTROLLED STUDY; HEAD TWITCH; HUMAN; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PREPULSE INHIBITION; PSYCHOANALYSIS; PSYCHOSIS; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DYSKINESIA; HYPERKINESIA; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY GATING; SPRAGUE DAWLEY RAT;

AMPHETAMINE; AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DYSKINESIAS; FENFLURAMINE; FLUOROBENZENES; HYPERKINESIS; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PIPERIDINES; PSYCHOTIC DISORDERS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SENSORY GATING; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN AGENTS; SEROTONIN RECEPTOR AGONISTS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; UREA;

EID: 80052957231     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32834aff98     Document Type: Article

References (48)

1. Aarsland D, Larsen JP, Cummins JL, Laake K (1999). Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595-601. (Pubitemid 29218155)
2. Balcioglu A, Zhang K, Tarazi FI (2003). Dopamine depletion abolishes apomorphine-and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience 119:1045-1053. (Pubitemid 36776454)
3. Ballanger B, Strafella AP, Van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH (2010). Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67:416-421.
4. Bishop C, Kamdar DP, Walker PD (2003). Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine- lesioned rats. Synapse 50:164-170. (Pubitemid 37152150)
5. Bishop C, Daut GS, Walker PD (2005). Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology 49:350-358. (Pubitemid 41112822)
6. Boulet S, Mounayar S, Poupard A, Bertrand A, Jan C, Pessiglione M, et al. (2008). Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci 28: 9575-9584.
7. Bruno JP, Jackson D, Zigmond MJ, Stricker EM (1987). Effect of dopamine-depleting brain lesions in rat pups: role of striatal serotonergic neurons in behavior. Behav Neurosci 101:806-811. (Pubitemid 18009676)
8. Calabresi P, Mercuri NB, Sancesario G, Bernardi G (1993). Electrophysiology of dopamine-denervated striatal neurons: implications for Parkinson's disease. Brain 116 (Pt 2):433-452. (Pubitemid 23104057)
9. 2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist-than dopamine agonist-induced hyperac-tivity in mice. J Neural Transm 106:123-129. (Pubitemid 29137509)
10. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ (1998). Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci 861:288-289. (Pubitemid 29047755)
11. Eng ML, Welty TE (2010). Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother 8:316-330.
12. Factor SA, Molho ES, Podskalny GD, Brown D (1995). Parkinson's disease: drug-induced psychiatric states. Adv Neurol 65:115-138.
13. Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, Woods JH (2010). Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2, 5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther 335:728-734.
14. Fenelon G (2008). Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13 (3 Suppl 4):18-25. (Pubitemid 351532445)
15. Fiedman JH (2010). Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord 16:553-560.
16. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2004). Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24:9434-9440. (Pubitemid 39426179)
17. Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G (2010). A 12-year population-based study of psychosis in Parkinson's disease. Arch Neurol 67:996-1001.
18. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, et al. (2007). ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 322: 862-870. (Pubitemid 47105818)
19. Gerfen CR (2003). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist 9: 455-462. (Pubitemid 37467358)
20. Geyer MA, Swerdlow NR (2001). Measurement of startle response, prepulse inhibition, and habituation. Curr Prot Neurosci 8.7.1-8.7.15 Chapter 8.
21. Goetz CG, Stebbins GT (1993). Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43:2227-2229. (Pubitemid 23346953)
22. Hely MA, Morris JG, Reid WG, Trafficante R (2005). Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190-199. (Pubitemid 40361122)
23. Henderson MJ, Mellers JDC (2000). Psychosis in Parkinson's disease: 'between a rock and a hard place'. Int Rev Psychiatry 12:319-334.
24. Hu XT, Wachtel SR, Galloway MP, White FJ (1990). Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. J Neurosci 10:2318-2329.
25. Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, et al. (2010). Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 25:1399-1408.
26. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369. (Pubitemid 32205190)
27. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM (2004). Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63:293-300. (Pubitemid 38971129)
28. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
29. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. (2010). Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 35:881-892.
30. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005). Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopa-minergic-induced hallucinations in Parkinson's disease. Mov Disord 20: 958-963. (Pubitemid 41419510)
31. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. 4th edition New York: Academic Press.
32. Pifl C, Nanoff C, Schingnitz G, Schutz W, Hornykiewicz O (1992). Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease. J Neurochem 58:1997-2004.
33. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007). Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 22:313-318. (Pubitemid 46569682)
34. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL (1998). Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245:151-154. (Pubitemid 28287345)
35. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
36. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995). [1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane]-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101-112.
37. Shotbolt P, Samuel M, Fox C, David AS (2009). A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 5: 327-332.
38. The French Clozapine Parkinson Study Group (1999). Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353:2041-2042.
39. The Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340:757-763.
40. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. (2006). Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N- (1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2 R,3 R)-dihydroxybutanedioate (2: 1) (ACP-103), a novel 5-hydroxytrypta-mine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317:910-918.
41. Varty GB, Bakshi VP, Geyer MA (1999). M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharma-cology 20:311-321. (Pubitemid 29099762)
42. Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, Kennett GA (2001). Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav 69:643-652. (Pubitemid 32758752)
43. Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, et al. (2006). Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders 21:1879-1891. (Pubitemid 44848934)
44. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, et al. (2001). 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268-276. (Pubitemid 32905144)
45. Weintraub D, Stern MB (2005). Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 13:844-851. (Pubitemid 46638672)
46. Zahodne LB, Fernandez HH (2008). Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 25:665-682.
47. Zhang X, Andren PE, Svenningsson P (2007). Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol Behav 92:29-33. (Pubitemid 47374252)
48. Zhou FC, Bledsoe S, Murphy J (1991). Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556:108-116.